Sử dụng thuốc chống trầm cảm và nguy cơ co giật: một phân tích tổng hợp từ các nghiên cứu quan sát

Wei Yang1, Yong-hui Jia2, Hai-yin Jiang3, Ai-juan Li2
1Department of Oncology, Hangzhou Red Cross Hospital, Hangzhou, China
2Pharmacy Department, The 960th Hospital of PLA, Jinan, China
3State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Tóm tắt

Mối liên quan giữa việc sử dụng thuốc chống trầm cảm và nguy cơ co giật vẫn còn gây tranh cãi. Do đó, phân tích tổng hợp này đã xem xét việc sử dụng thuốc chống trầm cảm ảnh hưởng đến nguy cơ co giật như thế nào. Để xác định các nghiên cứu quan sát liên quan, chúng tôi đã tiến hành tìm kiếm hệ thống trên PubMed và Embase của các nghiên cứu được công bố đến tháng 5 năm 2023. Các mô hình ngẫu nhiên đã được sử dụng để ước lượng nguy cơ tương đối chung. Phân tích tổng hợp của chúng tôi bao gồm tám nghiên cứu với 1.709.878 cá nhân. Kết quả của chúng tôi cho thấy rằng các chất ức chế tái hấp thu serotonin chọn lọc (SSRI) (tỷ lệ odds [OR] 1.48, khoảng tin cậy [CI] 95% 1.32–1.66; P < 0.001) và các chất ức chế tái hấp thu noradrenaline chọn lọc (SNRI) (OR 1.65, 95% CI 1.24–2.19; P = 0.001), nhưng không phải thuốc chống trầm cảm ba vòng (TCA) (OR 1.27, 95% CI 0.84–1.92; P = 0.249), có liên quan đến nguy cơ gia tăng co giật. Phân tích phân nhóm cho thấy OR là 2.35 (95% CI 1.7, 3.24; P < 0.001) ở những người sử dụng thuốc chống trầm cảm ngắn hạn (< 30 ngày). Các phát hiện của phân tích tổng hợp này hỗ trợ nguy cơ gia tăng co giật ở những người sử dụng thuốc chống trầm cảm thế hệ mới, mở rộng kiến thức trước đó bằng cách chỉ ra nguy cơ rõ ràng hơn ở những người sử dụng ngắn hạn.

Từ khóa

#thuốc chống trầm cảm #nguy cơ co giật #SSRI #SNRI #TCA #phân tích tổng hợp

Tài liệu tham khảo

Harmer CJ, Duman RS, Cowen PJ (2017) How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 4(5):409–418. https://doi.org/10.1016/s2215-0366(17)30015-9 Kazdin AE, Wu CS, Hwang I, Puac-Polanco V, Sampson NA, Al-Hamzawi A, Alonso J, Andrade LH, Benjet C, Caldas-de-Almeida JM, de Girolamo G, de Jonge P, Florescu S, Gureje O, Haro JM, Harris MG, Karam EG, Karam G, Kovess-Masfety V, Lee S, McGrath JJ, Navarro-Mateu F, Nishi D, Oladeji BD, Posada-Villa J, Stein DJ, Üstün TB, Vigo DV, Zarkov Z, Zaslavsky AM, Kessler RC (2023) Antidepressant use in low- middle- and high-income countries: a World Mental health surveys report. Psychol Med 53(4):1583–1591. https://doi.org/10.1017/s0033291721003160 Kumar M, Bajpai R, Shaik AR, Srivastava S, Vohora D (2020) Alliance between selective serotonin reuptake inhibitors and fracture risk: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 76(10):1373–1392. https://doi.org/10.1007/s00228-020-02893-1 Wang XY, Ying XH, Jiang HY (2023) Antidepressant use during pregnancy and the risk for gestational Diabetes: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 36(1):2162817. https://doi.org/10.1080/14767058.2022.2162817 Jiang HY, Chen HZ, Hu XJ, Yu ZH, Yang W, Deng M, Zhang YH, Ruan B (2015) Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 13(1):42–50e43. https://doi.org/10.1016/j.cgh.2014.06.021 Elger CE, Hoppe C (2018) Diagnostic challenges in Epilepsy: seizure under-reporting and seizure detection. Lancet Neurol 17(3):279–288. https://doi.org/10.1016/s1474-4422(18)30038-3 Larson EA, Accardi MV, Zhong Y, Paquette D, Authier S (2021) Drug-Induced seizures: considerations for underlying Molecular mechanisms. Int J Toxicol 40(5):403–412. https://doi.org/10.1177/10915818211040483 Magli G, Conti M, Polano R, Luzzu G, Fadda M, Sotgiu S, Casellato S (2021) Seizures associated with selective serotonin reuptake inhibitors: a case of pharmacologically induced epileptic myoclonia. Seizure 88:75–77. https://doi.org/10.1016/j.seizure.2021.03.031 Saffaei D, Lovett S, Rech MA (2020) New-Onset Seizure in Patient Medicated with Bupropion for Smoking Cessation: a Case Report. J Emerg Med 58(3):e145–e147. https://doi.org/10.1016/j.jemermed.2019.12.020 Ye C, Ninneman M, Christian JS, Zhang F, Musselman D (2018) Seizure Induced by a therapeutic dose of Venlafaxine ER: a Case Report. J Psychiatr Pract 24(2):117–120. https://doi.org/10.1097/pra.0000000000000298 Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J (2015) Antidepressant use and risk of Epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. BMC Psychiatry 15:315. https://doi.org/10.1186/s12888-015-0701-9 Coupland CA, Dhiman P, Barton G, Morriss R, Arthur A, Sach T, Hippisley-Cox J (2011) A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess 15 (28): 1-202, iii-iv https://doi.org/10.3310/hta15280 Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012. https://doi.org/10.1001/jama.283.15.2008 Higgins JP (2014) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration. Available at: www.cochrane-handbook.org [6 December 2014] Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. https://doi.org/10.1002/sim.1186 Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557 Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629 Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I (2006) The case of the misleading funnel plot. BMJ 333(7568):597–600. https://doi.org/10.1136/bmj.333.7568.597 Bloechliger M, Ceschi A, Rüegg S, Kupferschmidt H, Kraehenbuehl S, Jick SS, Meier CR, Bodmer M (2016) Risk of seizures Associated with antidepressant use in patients with depressive disorder: follow-up study with a nested case-control analysis using the Clinical Practice Research Datalink. Drug Saf 39(4):307–321. https://doi.org/10.1007/s40264-015-0363-z Sáez ME, González-Pérez A, Gaist D, Johansson S, Nagy P, García Rodríguez LA (2016) Risk of seizure associated with use of acid-suppressive Drugs: an observational cohort study. Epilepsy Behav 62:72–80. https://doi.org/10.1016/j.yebeh.2016.06.039 Wu CS, Liu HY, Tsai HJ, Liu SK (2017) Seizure risk Associated with antidepressant treatment among patients with depressive disorders: a Population-based case-crossover study. J Clin Psychiatry 78(9):e1226–e1232. https://doi.org/10.4088/JCP.16m11377 Finkelstein Y, Macdonald EM, Li P, Mamdani MM, Gomes T, Juurlink DN (2018) Second-generation anti-depressants and risk of new-onset seizures in the elderly. Clin Toxicol (Phila) 56(12):1179–1184. https://doi.org/10.1080/15563650.2018.1483025 Chu CS, Lee FL, Bai YM, Su TP, Tsai SJ, Chen TJ, Hsu JW, Chen MH, Liang CS (2023) Antidepressant Drugs use and Epilepsy risk: a nationwide nested case-control study. Epilepsy Behav 140:109102. https://doi.org/10.1016/j.yebeh.2023.109102 Wiggs KK, Lagerberg T, Quinn PD, Öberg AS, Larsson H, Chang Z, D’Onofrio BM (2023) A nationwide study of initiation of antidepressant pharmacotherapy and the risk of seizures. Epilepsy Res 192:107134. https://doi.org/10.1016/j.eplepsyres.2023.107134 Karadag N, Shadrin AA, O’Connell K, Hindley GFL, Rahman Z, Parker N, Bahrami S, Fominykh V, Cheng W, Holen B, Alvestad S, Taubøll E, Steen NE, Djurovic S, Dale AM, Frei O, Andreassen OA, Smeland OB (2023) Identification of novel genomic risk loci shared between common epilepsies and psychiatric disorders. Brain DOI. https://doi.org/10.1093/brain/awad038 Lesage F, Guillemare E, Fink M, Duprat F, Heurteaux C, Fosset M, Romey G, Barhanin J, Lazdunski M (1995) Molecular properties of neuronal G-protein-activated inwardly rectifying K + channels. J Biol Chem 270(48):28660–28667. https://doi.org/10.1074/jbc.270.48.28660 De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG (2014) Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics 55(6):536–547. https://doi.org/10.1016/j.psym.2014.01.010 Halawa I, Andersson T, Tomson T (2011) Hyponatremia and risk of seizures: a retrospective cross-sectional study. Epilepsia 52(2):410–413. https://doi.org/10.1111/j.1528-1167.2010.02939.x Warden SJ, Fuchs RK (2016) Do selective serotonin reuptake inhibitors (SSRIs) cause fractures? Curr Osteoporos Rep 14(5):211–218. https://doi.org/10.1007/s11914-016-0322-3